Search Result

Isoforms Recommended:	TXA₂/TP

Results for "

Thromboxane A2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Collagen (1) COX (6) Endogenous Metabolite (3) Ferroptosis (2) Histamine Receptor (2) Isotope-Labeled Compounds (4) JNK (2) Leukotriene Receptor (2) MDM-2/p53 (2) NF-κB (1) p38 MAPK (1) Phospholipase (1) Prostaglandin Receptor (53) Reactive Oxygen Species (2) Ser/Thr Protease (3) Thrombopoietin Receptor (4) Xanthine Oxidase (2)
By Research Areas:	Cancer (9) Cardiovascular Disease (46) Endocrinology (15) Inflammation/Immunology (18) Metabolic Disease (4) Neurological Disease (6)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0428B

Ozagrel hydrochloride 1 Publications Verification OKY-046 hydrochloride	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC₅₀ of 53.12 μM .

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-113350

Thromboxane A2 TXA2	Prostaglandin Receptor Endogenous Metabolite	Inflammation/Immunology Endocrinology Cancer
Thromboxane A2 (TXA2) is a prostanoid mediator produced by the metabolism of Arachidonic acid (HY-109590) through the cyclooxygenase pathway. Thromboxane A2 activates the thromboxane-prostanoid (TP) receptors. Thromboxane A2 is a potent vasoconstrictor eicosanoid. Thromboxane A2 (TXA2) leads to potent vasoconstriction by stimulation of smooth muscle cells. Thromboxane A2 acts as s tonic immunoregulator to regulate adaptive immune responses .

HY-116281

ICI D1542	Prostaglandin Receptor	Cardiovascular Disease
ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .

HY-106066

Dazmegrel UK38485	Prostaglandin Receptor	Cardiovascular Disease
Dazmegrel (UK-38485) is a thromboxane synthetase inhibitor which inhibits Thromboxane A2 (TXA2) synthesis and exhibits antiplatelet vasodilator effects. Dazmegrel can be utilized in thrombosis research .

HY-123328

AGN 191976	Prostaglandin Receptor	Cardiovascular Disease
AGN 191976 is a potent and selective thromboxane A₂-sensitive (TP) receptor agonist with EC₅₀ values of 0.23 nM and 24 nM in rat aorta and human platelets, respectively. AGN 191976 has potent IOP-lowering effects in dogs and monkeys. AGN 191976 can be used to study vascular biology and the role of thromboxane A₂ in vascular function .

HY-160664

TP receptor antagonist-2	Prostaglandin Receptor	Cardiovascular Disease
TP receptor antagonist-2 (example 7n) is a thromboxane A₂ receptor (TP receptor) antagonist, with IC₅₀ values of 5.64 and 5.27 μM for TPα and TPβ, respectively. TP receptor antagonist-2 inhibits platelet aggregation .

HY-116560

ONO-8809	Histamine Receptor	Inflammation/Immunology
ONO-8809 is a Thromboxane A2 receptor antagonist. ONO-8809 inhibits the LTC4-induced airway hyperresponsiveness to histamine in a dose-dependent manner .

HY-B0428BR

Ozagrel (hydrochloride) (Standard)	Prostaglandin Receptor	Cardiovascular Disease
Ozagrel (hydrochloride) (Standard) is the analytical standard of Ozagrel (hydrochloride). This product is intended for research and analytical applications. Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC₅₀ of 53.12 μM .

HY-105120A

Vapiprost hydrochloride GR 32191 hydrochloride	Prostaglandin Receptor	Others
Vapiprost hydrochloride (GR 32191 hydrochloride) is a thromboxane A2 receptor antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC₅₀ of less than 2.1×10 ^-8 M .

HY-W273690

Pentifylline 1-Hexyltheobromine; Hexyltheobromine	Collagen	Cardiovascular Disease
Pentifylline is a vasodilator with anti-inflammatory activity. Pentifylline inhibits platelet aggregation and thromboxane A2 synthesis, reduces the release of free radicals, and decreases the production of type 1 collagen and laminin in fibroblasts. Pentifylline has the potential to be studied in acute ischemic stroke .

HY-130304

8-Isoprostaglandin E2 iPE2-III	Prostaglandin Receptor	Cardiovascular Disease
8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A₂ (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .

HY-160615

TP receptor antagonist-1	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
TP receptor antagonist-1 (compound 7m) is a thromboxane A₂ receptor (TP receptor) antagonist, with IC₅₀ values of 9.46 μM for TPa and 8.49 μM for TPb, respectively. TP receptor antagonist-1 can be used for the research of cardiovascular disease .

HY-19189

Terbogrel BIBV 308SE	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A2 synthase inhibitor, with both IC₅₀s of about 10 nM.

HY-A0221

Ridogrel R 68070	Prostaglandin Receptor	Inflammation/Immunology
Ridogrel (R 68070) is an orally active *combined thromboxane* A2 synthetase** inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker. Ridogrel is potent antiplatelet agent. Anti-inflammatory activities .

HY-124150

BM567	Prostaglandin Receptor	Cardiovascular Disease
BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A₂ receptor (TXR) antagonists and thromboxane A₂ synthase (TXS) inhibitors, with IC₅₀s of 1.1 and 12 nM, respectively .

HY-158332

Sulotroban SKF-95587; BM-13177	Prostaglandin Receptor	Cardiovascular Disease
Sulotroban (SKF-95587; BM-13177) is a selective antagonist for thromboxane A2 receptor (TXA2 Receptor). Sulotroban exhibits inhibitory activity against carbocyclic thromboxane A2- and endoperoxide-induced vasoconstrictor. Sulotroban inhibits platelets aggregation .

HY-101606

Etersalate Eterylate; Etherylate	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Etersalate inhibits platelet function and decreases thromboxane A2 (TXA2) levels.

HY-U00072

RS-601	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
RS-601 is a novel *leukotriene D4 (LTD4)/thromboxane* A2 (TxA2)** dual receptor antagonist, with antiasthmatic activities.

HY-U00253

KP496	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
KP496 is a selective, dual antagonist for Leukotriene D4 receptor and Thromboxane A2 receptor.

HY-101700

LCB-2853	Prostaglandin Receptor	Cardiovascular Disease
LCB-2853 is an antagonist of thromboxane A2 (TXA2) receptor, with antiplatelet and antithrombotic activities.

HY-101692

AZ-1355	Prostaglandin Receptor	Metabolic Disease Endocrinology
AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I₂/thromboxane A₂ ratio in vitro.

HY-130444

PTA2 PinaneThromboxane A2	Biochemical Assay Reagents	Others
PTA2 (Pinane thromboxane A2) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-114564

Satigrel E5510	Prostaglandin Receptor	Cardiovascular Disease
Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC₅₀: 0.081 μM) and PGHS2 (IC₅₀: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC₅₀: 15.7 μM, 39.8 μM and 62.4 μM, respectively) .

HY-126923

*2,3-Dinor thromboxane* B2** 2,3-Dinor-TXB2	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
2,3-Dinor thromboxane B2 (2,3-Dinor-TXB2), a metabolite of urine, serves as an indicator of the production of thromboxane A2 (TxA2) in the body, and can be used as a tool to study the role of thromboxane in various pathophysiological processes in the human body .

HY-121720

L 657925	Prostaglandin Receptor	Cardiovascular Disease
L 657925 is a potent thromboxane A2 (TXA2) antagonist. L 657925 selectively abolishes ONO 11113-evoked transient increment in [Ca2 ²⁺] .

HY-106080A

Furegrelate sodium U-63557A	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-111271A

L 888607 Racemate	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
L 888607 Racemate is a selective prostaglandin D₂ receptor subtype 1 (DP1) antagonist, with K_is of 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively.

HY-106080

Furegrelate U-63557A free acid	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent .

HY-B0745

Ramatroban BAY u3405	Prostaglandin Receptor	Inflammation/Immunology Endocrinology Cancer
Ramatroban is a selective thromboxane A₂ (TxA₂, IC₅₀=14 nM) antagonist, which also antagonizes CRTH2 (IC₅₀=113 nM) by inhibiting PGD₂ binding.

HY-19249

Z-335 sodium	Prostaglandin Receptor	Metabolic Disease Inflammation/Immunology
Z-335 sodium is an orally active thromboxane a₂ (TXA₂) receptor antagonist, with IC₅₀ values of 29.9 nM and 32.5 nM for human and Guinea pig platelets, respectively .

HY-W612338

9-Oxononanoic acid 9-ONA	Phospholipase Prostaglandin Receptor	Cardiovascular Disease
9-Oxononanoic acid (9-ONA) is secondary reaction product of lipid peroxidation. 9-Oxononanoic acid induces phospholipase A2 (PLA2) activity and thromboxane A2 (HY-113350) production (TXA2). 9-Oxononanoic acid induces the platelet aggregation in human blood. 9-Oxononanoic acid is orally active .

HY-119890

Isbogrel CV-4151	Prostaglandin Receptor	Cardiovascular Disease Cancer
Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID₅₀ value of 0.04 mg/kg .

HY-18763A

Indobufen sodium Ibustrin sodium	COX	Cardiovascular Disease
Indobufen sodium is a platelet aggregation inhibitor. Indobufen sodium is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen sodium suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen sodium down-regulates tissue factor (TF) in monocytes .

HY-101236

ICI 192605	Prostaglandin Receptor	Endocrinology
ICI 192605 is a potent TXA2R (thromboxane A2 receptor) antagonist as cell signaling prostaglandin. ICI 192605 blocks contraction of isolated guinea pig trachea induced by U-46619 .

HY-18763

Indobufen 1 Publications Verification Ibustrin	COX	Cardiovascular Disease
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-121018

Daltroban BM-13505; SKF 96148	Prostaglandin Receptor	Cardiovascular Disease
Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury .

HY-106080AR

Furegrelate sodium (Standard) U-63557A (Standard)	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-B1735

Picotamide	Prostaglandin Receptor	Cardiovascular Disease
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .

HY-B0745S

Ramatroban-d4 BAY u3405-d₄	Isotope-Labeled Compounds Prostaglandin Receptor	Inflammation/Immunology Endocrinology Cancer
Ramatroban-d₄ is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.

HY-123400A

iso-Samixogrel iso-DTTX30; iso-DT-TX 30 SE	Prostaglandin Receptor	Cardiovascular Disease
Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.

HY-105120

Vapiprost GR 32191	Prostaglandin Receptor	Others
Vapiprost (GR 32191) is a thromboxane A2 receptor (TXA2 Receptor) antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC₅₀ of less than 2.1×10 ^-8 M .

HY-129230

Triletide	Endogenous Metabolite	Cardiovascular Disease
Triletide is a thromboxane A2 antagonist with good oral absorption activity. The biotransformation of Triletide mainly includes the formation of demethyl, deacetyl, demethyl-deacetyl and hydroxy derivatives. The distribution half-life of Triletide is about 1 hour, and the elimination half-life is about 5 hours .

HY-18763S

Indobufen-d5 Ibustrin-d₅	Isotope-Labeled Compounds COX	Cardiovascular Disease
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].

HY-111304

MF266-1	Prostaglandin Receptor Thrombopoietin Receptor	Inflammation/Immunology
MF266-1 is a selective E prostanoid receptor 1 (EP1) antagonist with an K_i value of 3.8 nM. MF266-1 also has moderate selectivity for thromboxane A2 receptor (TP). MF266-1 is promising for research of arthritis .

HY-18763R

Indobufen (Standard)	COX	Cardiovascular Disease
Indobufen (Standard) is the analytical standard of Indobufen. This product is intended for research and analytical applications. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-B0428D

(E/Z)-Ozagrel sodium (E/Z)-OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease
(E/Z)-Ozagrel (sodium) [(E/Z)-OKY-046 (sodium)] is an EZ configuration mixture of Ozagrel (sodium) (HY-B0428A). Ozagrel (sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel (sodium) is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC₅₀ of 53.12 μM .

HY-118736

Ganodermic acid S	Others	Cardiovascular Disease
Ganodermic acid S is an oxygenated triterpenoid, that can be isolated from the Chinese medicinal fungus Ganoderma lucidum (Fr.) Karst (Polyporaceae). Ganodermic acid S exerts a concentration dependent inhibition on the response of human gel-filtered platelets (GFP) to U-46619 (HY-108566), a thromboxane (TX) A2 mimetic .

HY-129851

NTP42	Prostaglandin Receptor	Cardiovascular Disease
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca ²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .

Cat. No.	Product Name	Type

HY-D0837

Imidazole

2 Publications Verification

Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene

Cell Assay Reagents

Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG₂ and PGH₂) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL ^Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

HY-130444

PTA2 PinaneThromboxane A2	Carbohydrates
PTA2 (Pinane thromboxane A2) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-D0837R

Imidazole (Standard)

Glyoxaline (Standard); 1,3-Diaza-2,4-cyclopentadiene (Standard)

Cell Assay Reagents

Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113350

Thromboxane A2 TXA2	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Endocrinology Cancer	Prostaglandin Receptor Endogenous Metabolite
Thromboxane A2 (TXA2) is a prostanoid mediator produced by the metabolism of Arachidonic acid (HY-109590) through the cyclooxygenase pathway. Thromboxane A2 activates the thromboxane-prostanoid (TP) receptors. Thromboxane A2 is a potent vasoconstrictor eicosanoid. Thromboxane A2 (TXA2) leads to potent vasoconstriction by stimulation of smooth muscle cells. Thromboxane A2 acts as s tonic immunoregulator to regulate adaptive immune responses .

HY-W612338

9-Oxononanoic acid 9-ONA	Structural Classification Arachis hypogaea L. Leguminosae Ketones, Aldehydes, Acids Source classification Plants	Phospholipase Prostaglandin Receptor
9-Oxononanoic acid (9-ONA) is secondary reaction product of lipid peroxidation. 9-Oxononanoic acid induces phospholipase A2 (PLA2) activity and thromboxane A2 (HY-113350) production (TXA2). 9-Oxononanoic acid induces the platelet aggregation in human blood. 9-Oxononanoic acid is orally active .

HY-118736

Ganodermic acid S	Triterpenes Structural Classification Microorganisms Ketones, Aldehydes, Acids Terpenoids Source classification	Others
Ganodermic acid S is an oxygenated triterpenoid, that can be isolated from the Chinese medicinal fungus Ganoderma lucidum (Fr.) Karst (Polyporaceae). Ganodermic acid S exerts a concentration dependent inhibition on the response of human gel-filtered platelets (GFP) to U-46619 (HY-108566), a thromboxane (TX) A2 mimetic .

Cat. No.	Product Name	Chemical Structure

HY-B0745S

Ramatroban-d4
Ramatroban-d₄ is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.

HY-18763S

Indobufen-d5
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].

HY-130304S

8-Isoprostaglandin E2-d4

8-Isoprostaglandin E2-d₄ (iPE2-III-d₄) is deuterium labeled 8-Isoprostaglandin E2. 8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A₂ (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .

HY-W699983

Imidazole-15N2

Imidazole- ¹⁵N₂ (Glyoxaline- ¹⁵N₂) is ¹⁵N labeled Imidazole. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG₂ and PGH₂) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL ^Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks